RCS - Genflow Biosciences - Genflow Launches New Development Program

Genflow BiosciencesAnnouncement

10/04/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250410:nRSJ4093Ea&default-theme=true

RNS Number : 4093E  Genflow Biosciences PLC  10 April 2025

10 April 2025

 

Genflow Biosciences Plc

Genflow Biosciences Launches New Ophthalmology Development Program

Signs MTA with Leading Ophthalmology Company

 

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"),
the only publicly listed longevity company in Europe, is excited to announce
the launch of a new development program in ophthalmology, focused on advancing
a novel gene therapy leveraging its proprietary Centenarian SIRT6 (cSIRT6).
This therapy will utilize a specially designed non-viral vector engineered for
precise delivery of Genflow's SIRT6 to the eye.  The therapy is designed to
combat ocular problems including several pathologies of the cornea and
glaucoma.

This initiative is part of Genflow's continued efforts to optimize its gene
therapy and proprietary Centenarian SIRT6. As part of this effort, Genflow has
signed a Material Transfer Agreement (MTA) with a leading ophthalmology
company, to collaborate on the design and development of the eye-targeted
cSIRT6 non-viral vector to target ocular diseases. These therapies will
leverage Genflow's proprietary SIRT6 Centenarian gene technology, in
combination with an advanced vector delivery system.

Said Dr. Eric Leire, CEO of Genflow Biosciences: "We are thrilled to advance
our ophthalmology program. The eye, as a closed and accessible compartment,
presents an ideal target for gene therapy. More importantly, we believe that
SIRT6 holds significant promise to transform the treatment landscape for
corneal endothelial disorders and glaucoma."

Contacts

 Genflow Biosciences  Harbor Access
 Dr Eric Leire, CEO   Jonathan Paterson, Investor Relations
 +32-477-495-881      +1 475 477 9401
                      Jonathan.Paterson@Harbor-access.com

 

 Corporate Brokers
 Capital Plus Partners Ltd
 Jon Critchley, +44 0203 821 6168

 

About Genflow Biosciences

 

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies to decelerate the aging process, with
the goal of promoting longer and healthier lives while mitigating the
financial, emotional, and social impacts of a fast-growing aging global
population. Genflow's lead compound, GF-1002, works through the delivery of a
centenarian variant of the SIRT6 gene which has yielded promising preclinical
results. Genflow's 12-month proof-of-concept clinical trial evaluating their
SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other
programs planned for 2025, include a clinical trial that will explore the
potential benefits of GF-1002 in treating MASH (Metabolic
Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver
disease for which there is no effective treatments. Please visit
www.genflowbio.com (http://www.genflowbio.com)   and follow the Company on
LinkedIn
(https://www.linkedin.com/company/genflow-biosciences/?viewAsMember=true) and
X (https://x.com/genflowbio) .

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEANLNEDFSEFA